133 related articles for article (PubMed ID: 33038688)
1. NFIB functions as an oncogene in estrogen receptor-positive breast cancer and is regulated by miR-205-5p.
Chen H; Yu C; Shen L; Wu Y; Wu D; Wang Z; Song G; Chen L; Hong Y
Pathol Res Pract; 2020 Dec; 216(12):153236. PubMed ID: 33038688
[TBL] [Abstract][Full Text] [Related]
2. NFIB is a potential target for estrogen receptor-negative breast cancers.
Moon HG; Hwang KT; Kim JA; Kim HS; Lee MJ; Jung EM; Ko E; Han W; Noh DY
Mol Oncol; 2011 Dec; 5(6):538-44. PubMed ID: 21925980
[TBL] [Abstract][Full Text] [Related]
3. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
4. Regulatory effect of LncRNA DRAIC/miR-149-5p/NFIB molecular network on autophagy of esophageal cancer cells and its biological behavior.
Li F; Zhou X; Chen M; Fan W
Exp Mol Pathol; 2020 Oct; 116():104491. PubMed ID: 32659236
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA OIP5-AS1 plays an oncogenic role in ovarian cancer through targeting miR-324-3p/NFIB axis.
Liu QY; Jiang XX; Tian HN; Guo HL; Guo H; Guo Y
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7266-7275. PubMed ID: 32706064
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A.
Qin H; Liu W
J Cell Physiol; 2019 Apr; 234(4):3526-3537. PubMed ID: 30443946
[TBL] [Abstract][Full Text] [Related]
7. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
Zhao Y; Li Y; Lou G; Zhao L; Xu Z; Zhang Y; He F
PLoS One; 2012; 7(6):e39102. PubMed ID: 22723937
[TBL] [Abstract][Full Text] [Related]
8. miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB).
Zhou M; Zhou L; Zheng L; Guo L; Wang Y; Liu H; Ou C; Ding Z
PLoS One; 2014; 9(6):e100620. PubMed ID: 24949940
[TBL] [Abstract][Full Text] [Related]
9. miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer.
Hui Z; Yiling C; Wenting Y; XuQun H; ChuanYi Z; Hui L
FEBS Lett; 2015 Mar; 589(7):812-21. PubMed ID: 25725194
[TBL] [Abstract][Full Text] [Related]
10. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
Wu H; Li J; Guo E; Luo S; Wang G
Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
[TBL] [Abstract][Full Text] [Related]
11. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB.
Zhang Q; Cao LY; Cheng SJ; Zhang AM; Jin XS; Li Y
Oncol Rep; 2015 Mar; 33(3):1335-41. PubMed ID: 25591821
[TBL] [Abstract][Full Text] [Related]
12. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.
Hossain A; Kuo MT; Saunders GF
Mol Cell Biol; 2006 Nov; 26(21):8191-201. PubMed ID: 16940181
[TBL] [Abstract][Full Text] [Related]
13. ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.
Campbell TM; Castro MAA; de Oliveira KG; Ponder BAJ; Meyer KB
Cancer Res; 2018 Jan; 78(2):410-421. PubMed ID: 29180470
[TBL] [Abstract][Full Text] [Related]
14. miR-4732-5p promotes breast cancer progression by targeting TSPAN13.
Wang YW; Zhao S; Yuan XY; Liu Y; Zhang K; Wang J; Zhu J; Ma R
J Cell Mol Med; 2019 Apr; 23(4):2549-2557. PubMed ID: 30701690
[TBL] [Abstract][Full Text] [Related]
15. MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression.
Menbari MN; Rahimi K; Ahmadi A; Elyasi A; Darvishi N; Hosseini V; Mohammadi-Yeganeh S; Abdi M
Life Sci; 2019 Nov; 237():116945. PubMed ID: 31605710
[TBL] [Abstract][Full Text] [Related]
16. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
17. miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44.
Sun L; Fang Y; Wang X; Han Y; Du F; Li C; Hu H; Liu H; Liu Q; Wang J; Liang J; Chen P; Yang H; Nie Y; Wu K; Fan D; Coffey RJ; Lu Y; Zhao X; Wang X
Theranostics; 2019; 9(26):8409-8425. PubMed ID: 31754405
[No Abstract] [Full Text] [Related]
18. GPER mediated estradiol reduces miR-148a to promote HLA-G expression in breast cancer.
Tao S; He H; Chen Q; Yue W
Biochem Biophys Res Commun; 2014 Aug; 451(1):74-8. PubMed ID: 25063027
[TBL] [Abstract][Full Text] [Related]
19. LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis.
Chen Q; Xu H; Zhu J; Feng K; Hu C
Biomed Pharmacother; 2020 Aug; 128():110289. PubMed ID: 32485570
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
Shen Y; Ye YF; Ruan LW; Bao L; Wu MW; Zhou Y
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
